Keywords: heplisav, seroprotection, engerix-b, berkeley, california, usa-based, dynavax
Heplisav: more seroprotection than Engerix-B
Article | 11 December 2006
Berkeley, California, USA-based Dynavax Technologies Corp has reported statistically-significant results from the primary endpoint analysis of a Phase III trial ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Elan puts up formal "for sale" notice
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
